Alnylam Pharmaceuticals ALNY Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $278.1M+200% | -$278.16M+36.8% | -$440.24M+61.1% | -$1.13B-32.6% | ||
| $55.66M-1.8% | $56.67M+4.8% | $54.05M+21.6% | $44.47M-6.5% | ||
| $348.24M+28.0% | $272.08M+22.7% | $221.68M-3.9% | $230.65M+39.2% | ||
| —— | $86.55M— | —— | $45.6M-56.8% | ||
| —— | -$13.59M+26.0% | -$18.37M-154% | $34.14M+29.2% | ||
| —— | —— | —— | $191.77M+117% | ||
| $124.5M+3,956% | -$3.23M— | —— | —— | ||
| —— | -$38.99M-1,539% | -$2.38M-1,244% | -$177K— | ||
| -$52.94M+77.5% | -$235.45M-528% | $55.02M+183% | -$66.07M— | ||
| —— | -$3.02M— | —— | —— | ||
| $524.08M+6,405% | -$8.31M— | —— | -$541.27M+15.6% | ||
| $58.7M+71.2% | $34.28M-44.9% | $62.21M-13.7% | $72.06M-5.6% | ||
| $1.31B-20.2% | $1.63B-10.3% | $1.82B-7.8% | $1.98B+19.4% | ||
| $473.5M— | —— | -$336.35M— | —— | ||
| $250.03M-17.5% | $302.95M+105% | $147.46M-43.1% | $259.36M— | ||
| —— | —— | —— | —— | ||
| —— | $294.16M+70.9% | $172.13M-59.6% | $425.75M-65.9% | ||
| —— | -$15.24M-334% | $6.52M— | —— | ||
| $690.16M— | —— | -$53.67M— | —— | ||
| $218.71M+224% | $67.58M+110% | $32.12M-29.0% | $45.24M— | ||
| —— | $14.36M+138% | $6.02M+127% | $2.65M— | ||
| —— | -$3.02M— | —— | —— | ||
| $124.5M+3,956% | -$3.23M— | —— | —— | ||
| $238.4M+87.5% | $127.13M+19.3% | $106.55M— | —— | ||
| —— | $127.13M+19.3% | $106.55M+2.3% | $104.2M-10.6% | ||
| $59.78M— | —— | —— | $89.95M+114% | ||
| $250.03M-17.5% | $302.95M+105% | $147.46M-43.1% | $259.36M+5.3% | ||
| $6M— | $0— | $0— | —— | ||
| —— | —— | —— | —— | ||
| —— | —— | $0— | —— | ||
| —— | $0— | $0— | —— | ||
| $59.78M-22.4% | $77.08M— | —— | $98.45M+134% | ||
| $22.48M+131% | $9.73M+279% | $2.57M+154% | $1.01M— | ||
| —— | $14.36M+138% | $6.02M+127% | $2.65M— | ||
| $465.38M+1,193% | -$42.59M— | —— | -$613.33M+14.6% | ||
| $465.38M+1,193% | -$42.59M— | —— | -$613.33M+14.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Alnylam Pharmaceuticals generate?
- Alnylam Pharmaceuticals (ALNY) generated $714.9M in operating cash flow over the trailing twelve months.
- What is Alnylam Pharmaceuticals's free cash flow?
- After $71.6M of capital expenditures, Alnylam Pharmaceuticals's free cash flow was $643.3M over the trailing twelve months, up 931.4% year over year.
- Where does Alnylam Pharmaceuticals's cash flow data come from?
- Every line is extracted from Alnylam Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
